| |
FOR IMMEDIATE RELEASE
Contact:
Jim Parina
724-935-7029
jparina@expressionanalysis.com
Expression Analysis Signs New Agreement to Provide Genotyping Services to GlaxoSmithKline
Durham, NC – August 1, 2006: Expression Analysis, Inc. a full-service microarray processing, analysis and data management organization, has entered into an agreement with GlaxoSmithKline to provide microarray based genotyping services.
"We are pleased to support GSK microarray-based genotyping requirements,” said Steve McPhail, President and CEO of Expression Analysis. “Expression Analysis has developed the expertise and infrastructure to provide our pharmacogenomic clients with significant value based on our knowledge of microarray-based technology and the dedication of our staff to providing high-quality results. This agreement advances our goal of supporting pharmacogenomic studies in clinical trials.”
Expression Analysis, in collaboration with the CDER and Schering-Plough became the first company to submit electronic microarray data to the FDA in 2003 to assist the Agency in understanding how this data might be used in a regulatory submission. In 2004, Expression Analysis became the first microarray processing laboratory in the world to achieve compliance with Good Laboratory Practice regulations and CLIA registration in 2005. Over the past two years, the company has been developing its expertise in the processing of genotyping microarrays, interpretation of results and the application of results for pharmacogenomic discovery. These and other collaborative activities, including standardization initiatives and development of expertise in a variety of blood-based protocols, have allowed the company to build its infrastructure to facilitate the use of microarray technology in support of pharmaceutical clinical trials. Expression Analysis continues to develop its proficiency to service the needs of the pharmaceutical industry.
About Expression Analysis
Expression Analysis, Inc., (EA) (www.expressionanalysis.com) is a full-service microarray genomics testing and analysis organization dedicated to providing clients with the highest quality genomic processing and data analysis services using Affymetrix GeneChip® brand technology. In 2004, EA became the first microarray services facility, worldwide, to provide GLP-compliant services. EA is a U.S.-based authorized service provider for Affymetrix (www.affymetrix.com), a California-based company that develops and commercializes systems to help researchers explore the relationship between genes and human health.
|
|
